EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers

Bilal Tariq, Chester Lin, Vaibhav Mundra, Yang Gao, Dan Zhang, Ying C Ou

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.1584 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Bilal Tariq und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Pharmacometrics, BeOne Medicines Ltd, San Carlos, CA, USA. Hauptthemen laut MEDLINE: Food-Drug Interactions, Pyrimidines, Pyrazoles, Piperidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zanubrutinib is a next‐generation Bruton tyrosine kinase inhibitor approved for treating B‐cell malignancies. Two phase 1 studies evaluated a new 160‐mg zanubrutinib tablet versus 80‐mg capsules. In study BGB‐3111‐115 (n = 43), a randomized 3‐period crossover trial, relative bioavailability and food effects were assessed. Under fasted conditions, systemic exposure (area under the concentration‐time curve [AUC]) was comparable between tablets and capsules at both 160‐ and 320‐mg doses. A high‐fat meal increased tablet maximum plasma concentration (C max ) by 47%‐79% but had minimal effect on AUC (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Food-Drug InteractionsPyrimidinesPyrazolesPiperidinesProtein Kinase InhibitorsHumansTherapeutic EquivalencyCross-Over StudiesMaleAdultBiological AvailabilityTabletsFemaleYoung AdultHealthy VolunteersMiddle AgedArea Under CurveCapsulesAdministration, OralFastingAdolescent

Stichwörter der Autor:innen

BTK inhibitorbioequivalenceclinical pharmacologyfood effectpharmacokinetics

Substanzen

TabletsPyrimidinesPyrazoleszanubrutinibPiperidinesCapsulesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Clinical Pharmacology & Pharmacometrics, BeOne Medicines Ltd, San Carlos, CA, USA.
  • Biostatistics, BeOne Medicines Ltd, San Carlos, CA, USA.
  • Chemistry Analytical Research & Development, BeOne Medicines Ltd, Suzhou, China.

Zitieren

APA

Tariq, B., Lin, C., Mundra, V., Gao, Y., Zhang, D., & Ou, Y. C. (2026). Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1584

Vancouver

Tariq B, Lin C, Mundra V, Gao Y, Zhang D, Ou YC. Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.1584

BibTeX
@article{Tariq2026,
  author = {Tariq, Bilal and Lin, Chester and Mundra, Vaibhav and Gao, Yang and Zhang, Dan and Ou, Ying C},
  title = {Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.1584}
}
Kostenlos starten →